Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials
Titel:
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials
Auteur:
Ramalingam, S.S. O'Byrne, K. Boyer, M. Mok, T. Jänne, P.A. Zhang, H. Liang, J. Taylor, I. Sbar, E.I. Paz-Ares, L.